intercellular adhesion molecule (ICAM)-3 is a recently described member of the immunoglobulin superfamily and, as such, is closely related to ICAM-1 and fCAM-2. All three [CAMS are cognate for the counter-receptor lymphocyte function associated antigen-1 (LFA-1. CDlla/CD18). Unlike lCAM-1 and lCAM-2. ICAM-3 is constitutivcly expressed at high levels on resting leucocytes. We investigated the expression and function of ICAM-3 in normal skin (n^5). as well as its expression in psoriasis (fj=4), atopic eczema (n^4), allergic (rhus) contact dermatitis (n^3), and cutaneous T-cell lymphoma (CTCL, (1^2). Five-micrometre cryostat sections of skin were stained using monoclonal antibodies to ICAM-3 and a well characterized immunoperoxidase technique. In normal skin, ICAM-3 was expressed by all cutaneous leucocytes but most striking was the strong expression of ICAM-3 by Langerhans cells within both epidermis and dermis. This observation was confirmed by double-labelling with CDla and negative staining with an IgGl isotype control. In psoriasis, atopic eczema, allergic contact dermatitis, and CTCL, ICAM-3 was co-expressed on all CDla^ cells, although, in psoriasis, the intensity of ICAM-3 expression was reduced. Functional blocking experiments were performed to determine whether the observed ICAM-3 expression on Langerhans cells was functionally important in antigen presentation, CD4^ T cells were prepared from peripheral blood and lO'' CD4* T cells combined with iC epidermal cells harvested from keratome biopsies of normal skin of an individual allogeneic to the T-cell donor. Addition of SO fig anti-ICAM-3 to the co-culture resulted in a consistent (50%) reduction in degree of alloantigen presentation by Langerhans cells lo T cells. Inhibition was 77% of that produced by the addition of anti-LFA-1.
These data indicate that ICAM-3 is constitutively expressed by Langerhans cells and is a major ligand for LFA-1 on CD4+ T cells during their response to Langerhans cells. Because fresh Langerhans ceils constitutively express little ICAM-1, whereas ICAM-3 is constitutively expressed at high levels, it would appear that lCAM-3 is the dominant functional ICAM on in situ Langerhans cells in the normal epidermis.
Three immunoglobulin superfamily members, intercellular adhesion molecules (ICAM)-l, ICAM-2 and ICAM-?, in conjunction with their ligand lymphocyte function-associated antigen-1 (LFA-1. CI)lla/CD18) are important facilitators of adhesion events in inflammation.' ^ ICAM-1, ICAM-2 and ICAM-3 are membrane glycoproteins whose structure and immunobiology are well characterized.""^ ICAM-1 has live immunoglobulin-Iikc domains** whereas ICAM-2 contains only two such domains: however, these have ib% sequence homology to the tirst two domains of ICAM-1.' The most recently identified member ofthe [CAM family is a 124.000 molecular weight glycosylated glycoprotein. ICAM-3, ~" that contains five immunoglobulin-like domains -the first two of which share 37% sequence homology with those of ICAM-2^'''-Although ICAM-3 is structurally similar to the other two ICAMs it differs from them in that it is constitutively expressed on resting lymphocytes and monocytes thereby implying potential importance in lymphocyte activation."* "
The distribution of ICAM-1 in normal and diseased skin is well characterized.'"*""* ICAM-l is constitutively expressed by dermal endothelial celis and is inducible on keratinocytes by gamma interferon.'"* tumour necrosis ;t'i 1995 British Association of Dermatologists '^ and by a variety of non-cytokines including phorbol ester.''^ urushiol.''^ and all-trans retinoiĉ "^. ICAM-l/LFA-1 interactions are instrumental in cutaneous leucocyte trafficking, keratinocyte/Ieucocyte adhesion, and antigen presentation by Langerhans cells. In contrast, in normal skin. ICAM-2 is probably expressed solely by endothelium and appears not to be inducibic on other cellular components ofthe epidermis or dermis. The distribution and function of lCAM-3 in normal and inflamed skin is poorly elucidated at present."" Using anti-ICAM-3 monoclonal antibodies we have investigated: (i) the expression of ICAM-3 in normal skin and inflammatory dermatoses. and (ii) the functional role of ICAM-3 as a costimulatory molecule in Langerhans cell/T-cell interactions.
Methods

Patients
Four mm skin biopsies were procured under 1% plain lignocaine anaesthesia from five normal volunteers and from the untreated involved skin of chronic plaque psoriasis |n -4). atopic eczema (n -4), allergic (rhus) contact dermatitis: a 48-h patch test to poison ivy/ poison oak mix 1:50 (w/v) in alcohol (HoUister Stier. Elkhart. IN. U.S.A.: n = 3) and plaque stage cutaneous T-cell lymphoma (CTCL. n -2). No patients were receiving systemic therapy for their disease at time of biopsy. All biopsies were orientated in optima! cutting temperature embedding medium (OCT. Miles Laboratories. Elkhart. IN. U.S.A.). snap frozen in liquid nitrogen, and stored at -7iy^C until use.
For proliferation assay studies, keratome biopsies were taken from normal buttock skin under local 1% plain lignocaine anaesthesia. Biopsies were taken using a Castro Viejo keratome set at 0-2 mm so that the majority of the biopsy was composed of epidennis.
The procurement of biopsies was performed under approval of the University of Michigan Medical Center Institutional Review Board.
Immunohistology
Five-micrometre cryostat sections were stained using monoclonal antibodies to ICAM-3 (ICRl and ICR8: ICOS Corporation. Bothell. WA, U.S.A.) and a wellcharacterized immunoperoxidase technique (Vectastain ABC kit. Vector Laboratories. Burlingame. CA. U.S.A.): 3-amino-9-ethyl carbazole was used as the chromogen and the sections were counterstained with 1% haematoxylin. Substitution ofthe primary antibody with an IgGi isotype control, and omission of the primary antibody, served as negative controls.
To ascertain whether ICAM-3 expression was localized to Langerhans cells, a double-labelling technique was used. Antibody ICRl was used to identify ICAM-3 and Leu 6 (Becton Dickinson, Burlingame, California. U.S.A.) labelled CDla' Langerhans cells. The tirst antibody was visualized with the avidin-biotin immunoperoxidase technique using 3.3'-diaminobenzidine as the chromogen and the second antibody was visualized using an alkaline phosphatase/anti-alkaline phosphatase technique, with fast blue as chromogen. as previously described.Ẽ Goat antimouse IgG-conjugated magnetic beads (Dynabeads. M-45(). DynaJ. Great Neck. NY. U.S.A.) were washed twice with PBS and 10% FBS. resuspended in RPMI 1640 plus 1% FBS, and added at a concentration of 3 (beads)/! PBL. Tbe PBL-bead mixture was incubated for 4Smin at 4C witii reguiar (Smin) agitation. The solution was then diluted to 10 mi with PBS pius \{)% FBS. and incubated for a furtiier 1S tnin at 4 C. again with Smin agitation. B celis. monocytes, naturai kiiier ceils, atid Ci)8+ T cells were removed from the PBL suspension by applying the tube containing them to a magnet for 3-S min. drawing tiie bead-attached celis to tbe tube wall, and thus allowing the unbound celis to be removed in the supernatant. Tiie removed supernatant was centrifuged at 1400 r.p.m. at 4 C for 8 min. Tbe viability of CD4 ^ -enriched cells present in tbe supernatant was assessed using trypan blue.
T-cell proUjeration assaij.
To eacb well of a 96-weii. round-bottom microfilter plate (Costar. Cambridge. MA. U.S.A.) was added SO//i of puriiied CD4+ T cells (lO"" cells) andlO' epidermal cells. Various experiments were performed in triplicate with addition of eitiier 50/ig anti-ICAM-3 (ICR8). 50^g IgGl isotype controi. or SO//g anti LFA-1 (CDlla/i8). Tbe cultures were incubated at 37 C ibr 6 days before pulsing witb 0-0 3 7 MBq per weil of triated thymidine. harvested 18 h later, and counted in a liquid scintiilation counter. Tbe mean ± standard error of tiie mean (SEM) count per minute (c.p.m.) was caiculated for each tripiicate of weiis.
Results
Jmmimohistology
Bolii antibodies to iCAM-3 (ICRl and ICR8) showed equivalent staining in normai and diseased skin. In normal sicin. tiie predominant, constitutive staining was of epidermai Langerhans ceils (Fig. 1) as confirmed by doubie-labeiling witb CDla (Fig. 2) . Staining with IgGl isotype controi was negative. Other cell types that stained were predominantiy of ieucocyte iineage but neitiier keratinocytes. fibroblasts nor endotheliai ceiis expressed lCAM-3.
Psoriasis, atopic eczema, ailergic contact dermatitis, and CTCL aiso demonstrated positive leucocyte staining for ICAM-3 (Figs 3-6 ). again with expression by Langerhans ceiis. confirmed by doubie-Iabelling (Fig.  4) in both epidermis and dermis. iCAM-3 expression by psoriatic epidermai Langerhans ceils was fainter than tiiat observed in either normal skin or tbe other dermatoses studied {Fig.. 3). In none of the four inflammatory dermatoses studied was ICAM-3 expressed on keratinocytes, tibroblasts or endotheiial ceiis (Eigs 3-6).
Proliferation assay
Combining aiiogeneic epidermai celis to antigenpresenting cell-depieted CD4^ T celis resuited in T-ceii proliferation tbat was not significantiy iniiibited by the addition oflgGl. isotype control imtnunoglobuiin (Fig.  7) . Addition of ICR8 (IgGl antibody to ICAM-3) to the epidermai ceii+CD4^ T-cell cuiture resuited in a 50 ±14% reduction in alloantigen presentation, as measured by T-cell proliferation. Inhibition of T-cell proliferation by addition of anti-LFA-1 was 65 ± 5%. Thus. anti-lCAM-3 inhibited T-cell proliferation t(i about 77% of that observed with anti-LFA-1, n= :> (Fig. 7) .
Discussion
In this study we have demonstrated that ICAM-3 is constitutively and strongly expressed by Langerhanii cells in situ in the epidermis of normal skin. ICAM-:1 expression is not limited to normal skin as it is also observed on dermal and epidermal Langerhans cells and cutaneous leucocytes in psoriasis, atopic eczema, allergic contact dermatitis and CTCL. The reduced ICAM-:! expression on epidermal Langerhans cells in psoriatic skin is not readily explicable, although it is in agreement with observations that similar reductions in CDla and FKC/3 occur in psoriasis.^" Furthermore, the presence of ICAM-3 on epidermal Langerhans cells appears to be integral for alloantigen presentation to CD4"^ T cells and their subsequent proliferative response.
Previous dermaloses has not been examined. ICAM-3 is not. however, unique to cutaneous cells as it has been described on cells of leucocyte lineage in a variety of organs including lymph node, spleen, liver, kidney. lung and rheumatoid synovium.""* Furthermore. ICAM-3 has rarely been observed on endothelium. although there is one report of its presence on endothelial ceils in lymphomas."
The observation that ICAM-3 is strongly and constitutively expressed by Langerhans cells in situ in normal epidermis indicates that this adhesion molecule is important in initial antigen presentation to T cells. Both ICAM-1 and ICAM-2 are costimulatory when ligated to LFA-l,^*"'^^ and ICAM-1 is costimulatory for activated T cells.^'^^ By contrast ICAM-3 is costimulatory for both resting as well as activated T cells'' and this may he a consequence of its high constitutive expression. In vivo, Langerhans cell expression of ICAM-1 is very low. although in vitro culture conditions significantly enhance ICAM-1 expression and such enhancement is concurrent with increased potency of antigen presentation. '' " Blocking antibody to ICAM-3 significantly abrogates alloantigen presentation and subsequent T-cell proliferation and this observation underscores the importance of ICAM-3 to Langerhans cell function. ICAM-3 should be added cell activation occurring in situ during the effector phase of intracutaneous immune reactions than it is during primary sensitization in the draining lymph node. In conclusion. ICAM-3 is probably the dominant functional ICAM on in situ Langerhans cells and is likely to be an integral molecule in the initiation of antigen-driven cutaneous inflammation.
Addendum in proof while this article was in proof two reports ^'^~ were published which verify the importance of ICAM-3 as a costimulatory molecule on Langerhans cells.
